{"id":"infanrixtm-hexa","safety":{"commonSideEffects":[{"rate":"10-50","effect":"Injection site reactions (pain, redness, swelling)"},{"rate":"10-30","effect":"Fever"},{"rate":"10-20","effect":"Irritability"},{"rate":"5-15","effect":"Drowsiness"},{"rate":"5-10","effect":"Loss of appetite"},{"rate":"1-5","effect":"Vomiting"}]},"_chembl":{"chemblId":"CHEMBL31747","moleculeType":"Small molecule","molecularWeight":"82.15"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains antigens from diphtheria toxoid, tetanus toxoid, acellular pertussis, inactivated poliovirus, hepatitis B surface antigen, and Haemophilus influenzae type b conjugate. These components trigger both humoral and cellular immune responses, leading to the production of protective antibodies and memory immune cells against each of these pathogens. The acellular pertussis component uses purified bacterial proteins rather than whole-cell antigen, reducing reactogenicity while maintaining immunogenicity.","oneSentence":"Infanrix hexa is a combination vaccine that stimulates the immune system to produce antibodies against six infectious diseases by presenting inactivated or toxoid antigens.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:15:55.160Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Active immunization against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and Haemophilus influenzae type b in infants and children"}]},"trialDetails":[{"nctId":"NCT00129116","phase":"PHASE2","title":"3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococcal Serogroup C Conjugate Vaccine, Each Administered at 2,3,4 Mths of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-03-01","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":388},{"nctId":"NCT00891176","phase":"PHASE3","title":"Persistence of Antibodies at 3, 4 and 6 Years of Age After Vaccination With Meningococcal, Pneumococcal and Hib Vaccines","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-05-14","conditions":"Neisseria Meningitidis, Haemophilus Influenzae Type b","enrollment":582},{"nctId":"NCT01457547","phase":"PHASE4","title":"Comparison of Immunogenicity and Reactogenicity of INFANRIX™ HEXA and HEXAVAC™ Vaccines as a Primary Vaccination Course","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-10","conditions":"Hepatitis B, Poliomyelitis, Diphtheria","enrollment":494}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6997,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"InfanrixTM hexa","genericName":"InfanrixTM hexa","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Biologic","firstApprovalDate":"","aiSummary":"InfanrixTM hexa is a vaccine that protects against Hepatitis B, Poliomyelitis, Diphtheria, Acellular Pertussis, Tetanus, and Haemophilus influenzae type b (Hib). It is a small molecule vaccine administered as a primary vaccination course.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}